반응식
BrC1C(N2CCN(C(NC3C=CC=CC=3)=O)CC2)=C2N=C(C3C=CC(N(C)C)=CC=3)NC2=NC=1.[Cl:35][C:36]1[C:37]([N:46]2[CH2:51][CH2:50][N:49]([CH2:52][CH3:53])[CH2:48][CH2:47]2)=[C:38]([N+:43]([O-])=O)[C:39]([NH2:42])=[N:40][CH:41]=1.[O-]S(S([O-])=O)=O.[Na+].[Na+].[N:62]1([CH2:67][C:68]2[CH:75]=[CH:74][C:71]([CH:72]=O)=[CH:70][CH:69]=2)[CH:66]=[CH:65][CH:64]=[N:63]1>C(O)C.CN(C=O)C>[N:62]1([CH2:67][C:68]2[CH:75]=[CH:74][C:71]([C:72]3[NH:42][C:39]4=[N:40][CH:41]=[C:36]([Cl:35])[C:37]([N:46]5[CH2:51][CH2:50][N:49]([CH2:52][CH3:53])[CH2:48][CH2:47]5)=[C:38]4[N:43]=3)=[CH:70][CH:69]=2)[CH:66]=[CH:65][CH:64]=[N:63]1참가 물질
실험 절차
This was prepared using the same procedure as for 4-(6-bromo-2-(4-(dimethylamino)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)-N-phenylpiperazine-1-carboxamide, but here using 5-chloro-4-(4-ethylpiperazin-1-yl)-3-nitropyridin-2-amine (25 mg, 0.087 mmol), DMF (0.15 mL), ethanol (0.85 mL), 1M Na2S2O4 (3 eq, 0.26 mmol, 0.26 mL) and 4-(1H-pyrazol-1-ylmethyl)benzaldehyde (1.1 eq, 0.096 mmol, 18 mg). After 6 h, concentration in vacuo and purification by preparative tlc (CH2Cl2-MeOH, 9:1) gave the product (9 mg, 24%) as a colourless solid; δH (500 MHz, DMSO-d6) 1.06 (t, J=7.2 Hz, 3H, NCH2CH3), 2.40 (q, J=7.1 Hz, 2H, NCH2CH3), 2.58 (t, br, J=3.8 Hz, 4H, piperazine N(CH2)2), 3.70 (t, J=3.9 Hz, 4H, piperazine N(CH2)2), 5.42 (s, br, 2H, PhCH2), 6.30 (t, J=2.1 Hz, 1H, pyrazole H-4), 7.35 (d, J=8.3 Hz, 2H, phenyl H-2 & H-6), 7.49 (d, J=1.5 Hz, 1H, pyrazole H-3 or H-5), 7.86 (d, J=2.2 Hz, 1H, pyrazole H-3 or H-5), 8.10 (s, 1H, imidazo[4,5-b]pyridine H-5), 8.13 (d, J=8.2 Hz, 2H, phenyl H-3 & H-5);
후처리
- customThis was prepared
- concentrationconcentration
- customin vacuo and purification by preparative tlc (CH2Cl2-MeOH, 9:1)
출처 및 근거
- ORD 기록
- ord-46078876396f475aaf528004e7d99dde
- 출처 데이터셋
- uspto-grants-2012_01
- 특허 번호
- US08088761B2
연결된 노트
불러오는 중…